120157-96-2

Usage

Uses

Used in Pharmaceutical and Medicinal Chemistry:
METHYL 4-((TERT-BUTOXYCARBONYLAMINO)METHYL)BENZOATE is used as a reagent for the protection of amino groups and as a precursor for the synthesis of various pharmaceutical compounds. The presence of the tert-butoxycarbonylamino group makes it useful for the introduction of amino groups into target molecules, playing a significant role in the development of pharmaceutical compounds.

Upstream product

• 34619-03-9 tert-butyldicarbonate 
• 6232-11-7 methyl 4-(aminomethyl)benzoate hydrochloride 
• 24424-99-5 di-tert-butyl dicarbonate 
• 1129-35-7 4-cyanobenzoic acid methyl ester 
• 1314538-55-0 potassium tert-butyl N-[(trifluorolambda-4-boranyl)methyl]carbamate 
• 338396-06-8 methyl 4-((N, N-dimethylsulfamoyl)oxy)benzoate 
• 161497-18-3 methyl 4-(methanesulfonyloxy)benzoate 
• 124-38-9 carbon dioxide 
• 1291065-84-3 C₂₆H₄₅NO₄Sn 
• 18107-18-1 diazomethyl-trimethyl-silane 
• 67-56-1 methanol 
• 33233-67-9 4-(tert-Butoxycarbonylaminomethyl)benzoic acid 
• 56-91-7 p-aminomethylbenzoic acid 
• 56161-89-8 4-(2-aminoethyl)-benzoic acid methyl ester-hydrochloride 

Downstream Products

• 774238-90-3 tert-butyl N-[[4-(hydroxymethyl)phenyl]methyl]-N-(methyl)carbamate 
• 1354657-73-0 tert-butyl {4-[2-(4-but-2-ynyloxybenzenesulfonyl)acetyl]benzyl}carbamate 
• 1428935-47-0 tert-butyl N-[[4-[5-[3-[bis(tert-butoxycarbonyl)amino]-6-(4-isopropylsulfonylphenyl)pyrazin-2-yl]isoxazol-3-yl]phenyl]methyl]-N-(trideuteriomethyl)carbamate 
• 1428935-46-9 tert-butyl N-[[4-[chloro-N-hydroxycarbonimidoyl]phenyl]methyl]-N-(trideuteriomethyl)carbamate 
• 1428935-45-8 tert-butyl N-[[4-[hydroxyiminomethyl]phenyl]methyl]-N-(trideuteriomethyl)carbamate 
• 1428935-44-7 tert-butyl N-[(4-formylphenyl)methyl]-N-(trideuteriomethyl)carbamate 
• 1428935-43-6 tert-butyl N-[[4-(hydroxymethyl)phenyl]methyl]-N-(trideuteriomethyl)carbamate 
• 1428935-42-5 methyl 4-[[tert-butoxycarbonyl(trideuteriomethyl)amino]methyl]benzoate 
• 733783-38-5 Methyl 4-[[N-ethyl-N-(tert-butoxycarbonyl)amino]methyl]benzoate 
• 216957-07-2 1-[4-(N-tert-butoxycarbonylaminomethyl)benzoyl]-4-[(6-chloronaphthalen-2-yl)sulfonyl]piperazine 
• 6757-31-9 methyl-4-carbamoylbenzoate 
• 547770-52-5 malonic acid 3,5-bis-dodecyloxy-benzyl ester 4-(tert-butoxycarbonylamino-methyl)-benzyl ester 
• 33233-67-9 4-(tert-Butoxycarbonylaminomethyl)benzoic acid 
• 123986-64-1 tert-butyl 4-hydroxymethylbenzylcarbamate 

Relevant academic research and scientific papers

A supramolecular oligophenylenevinylene-C60 conjugate

A new methanofullerene derivative with an ammonium subunit has been prepared and its ability to form a supramolecular complex with an oligophenylenevinylene (OPV)-crown ether conjugate evidenced by NMR, electrospray mass spectrometry and luminescence expe

Development of a selective matrix metalloproteinase 13 (MMP-13) inhibitor for the treatment of Osteoarthritis

Osteoarthritis (OA) is a chronic disorder that causes damage to the cartilage and surrounding tissues and is characterized by pain, stiffness, and loss of function. Current treatments for OA primarily involve providing only relief of symptoms but does not

HISTONE DEMETHYLASE INHIBITORS FOR TREATING CANCERS

The present disclosure provides a new series of 8-hydroxyquinoline derivatives/analogs that are potent KDM4 inhibitors with high activity and selectivity against KDM4 enzymes. Also disclosed are the pharmaceutical compositions comprising such 8-hydroxyqui

PROCESSES FOR MAKING COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE

The present invention relates to processes and intermediates for preparing compounds useful as inhibitors of ATR kinase, such as aminopyrazine-isoxazole derivatives and related molecules. The present invention also relates to compounds useful as inhibitors of ATR protein kinase. The invention relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and solid forms of the compounds of this invention. The compounds of this invention have formula (I) or (II) wherein the variables are as defined herein.

Pd-catalyzed Suzuki-Miyaura cross-coupling reactions between sulfamates and potassium Boc-protected aminomethyltrifluoroborates

Sulfamates were studied as the electrophilic partners in the palladium-catalyzed Suzuki-Miyaura cross-coupling reaction with potassium Boc-protected primary and secondary aminomethyltrifluoroborates. A broad range of substrates was successfully coupled to provide the desired products. Complex molecules containing a new carbon-carbon bond and an aminomethyl moiety could be prepared through this developed method.

Suzuki-Miyaura cross-coupling reactions of potassium boc-protected aminomethyltrifluoroborate with aryl and hetaryl mesylates

Palladium-catalyzed Suzuki-Miyaura cross-coupling reactions were studied with potassium Boc-protected aminomethyltrifluoroborate through C-O activation of various mesylate derivatives to afford the corresponding products in moderate to good yields.

Synthesis of arylglycine and mandelic acid derivatives through carboxylations of α-amido and α-acetoxy stannanes with carbon dioxide

Incorporation reactions of carbon dioxide (CO2) with N-Boc-α-amido and α-acetoxy stannanes were developed using CsF as a mild tin activator. Monoprotected α-amido stannanes could be used, and the corresponding arylglycine derivatives were obtained in moderate-to-high yields under 1 MPa (10 atm) of CO2 pressure. α-Acetoxy stannanes also underwent carboxylation to afford mandelic acid derivatives in excellent yields under ambient CO2 pressure. Both transformations enabled the synthesis of α-tertiary and α-quaternary carboxylic acid derivatives. In addition, the chirality of (S)-N-tert-butylsulfonyl-α- amido stannanes was transferred with up to 90% inversion of configuration at 100 °C.

NEW BRADYKININ B1 ANTAGONISTS

The invention relates to compounds of formula (I) where in R1, R1a, R1b, R2, R3 and X, X1, X2, X3 have the meaning as cited in the description and the claims. Said compounds are useful as Bradykinin B1 antagonists. The invention also relates to pharmaceutical compositions, the preparation of such compounds as well as the production and use as medicament.

NOVEL 2-QUINOLONE DERIVATIVE

A compound represented by the formula (1) or a pharmaceutically acceptable salt thereof which has a therapeutic or prophylactic effect on an SNS-related disease such as neuropathic pain. (1) wherein R1 and R2 independently represent

NITROGENOUS FUSED BICYCLIC COMPOUND

A novel nitrogenous fused bicyclic compound represented by the following general formula [1] or a pharmacologically acceptable salt of the compound. They have excellent SK channel blocking activity and are useful as a medicine. [I] (In the formula, R 0 represents hydrogen, halogeno, etc.; R 1 represents a group represented by the formula (a) or (b); A represents a group represented by the formula (X) or (Y); D 1 , D 2 and D 3 each represents N or CH; R 2 represents halogeno or optionally halogenated lower alkyl, etc.; R 3 represents hydrogen or lower alkyl; and Q represents lower alkylene.)